Core Points - TC BioPharm (Holdings) PLC announced a change in the ratio of its American Depositary Shares (ADSs) from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares, effective February 10, 2025 [1][2] - This change will function as a 1-for-20 reverse ADS split for ADS holders, with no impact on the underlying ordinary shares [2][3] - Holders of ADSs will need to surrender 20 ADSs for 1 new ADS, with fractional new ADSs not being issued; instead, fractional entitlements will be aggregated and sold, with net proceeds distributed to ADS holders [3] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data in acute myeloid leukemia [5][6] - The company is a leader in this field and the first to conduct phase II/pivotal clinical studies in oncology, currently running two investigator-initiated clinical trials for its gamma-delta T cell product line [6]
TCBP to Implement ADS Ratio Change